|
| We are delighted to announce that SenzaGen's GARDskin assay has been adopted by OECD as part of Test Guideline 442E for in vitro skin sensitization, which is a regulatory breakthrough for the GARD technology. As the first and only genomics and machine learning-based method, GARDskin has been approved for the third key event, dendritic cell activation. The scientific data published in the TG confirms the high performance and broad applicability of the method, bringing new opportunities to the field of in vitro skin sensitization testing. |
|
|
 |
| Watch this recorded webinar where our skin sensitization specialist Dr Andy Forreryd introduces the features and benefits of GARDskin and how the method can be used to fill data gaps during regulatory testing and R&D. |
|
|
|
 |
Our joint article with The Lubrizol Corporation regarding the applicability domain of GARDskin was published in the ALTEX Journal, providing new peer-reviewed evidence that GARD can predict chemicals traditionally considered “difficult-to-test”, for example indirectly acting haptens, hydrophobic substances and UVCBs, without an increased risk of false-negative classifications.
Read the full article |
|
|
 |
Following successful initial evaluation in 2021, Research Institute for Fragrance Materials, Inc. (RIFM) decided to test more ingredients with GARDskin Dose-Response, which has been adapted to identify the dose levels at which a fragrance can induce skin allergies when exposed to sunlight (photosensitization). RIFM’s continued trust in us affirms their appreciation of the many application areas that our GARD technology offers and can be adapted to.
Read more about RIFM’s photosensitization project and why it matters |
|
|
|
|
%20Color%20RGB.png)
